<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Beigene Ltd. — News on 6ix</title>
<link>https://6ix.com/company/beigene-ltd</link>
<description>Latest news and press releases for Beigene Ltd. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 10:01:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/beigene-ltd" rel="self" type="application/rss+xml" />
<item>
<title>BeOne Medicines to Announce First Quarter 2026 Financial Results on May 6</title>
<link>https://6ix.com/company/beigene-ltd/news/beone-medicines-to-announce-first-quarter-2026-financial-results-on-may-6</link>
<guid isPermaLink="true">https://6ix.com/company/beigene-ltd/news/beone-medicines-to-announce-first-quarter-2026-financial-results-on-may-6</guid>
<pubDate>Wed, 22 Apr 2026 10:01:00 GMT</pubDate>
<description>SAN CARLOS, Calif., April 22, 2026--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its first quarter 2026 financial results on Wednesday, May 6, 2026 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET.</description>
</item>
<item>
<title>BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership</title>
<link>https://6ix.com/company/beigene-ltd/news/beone-medicines-announces-fourth-quarter-and-full-year-2025-financial-results-highlighting-global-success-of-brukinsa-and-foundational-oncology-leadership</link>
<guid isPermaLink="true">https://6ix.com/company/beigene-ltd/news/beone-medicines-announces-fourth-quarter-and-full-year-2025-financial-results-highlighting-global-success-of-brukinsa-and-foundational-oncology-leadership</guid>
<pubDate>Thu, 26 Feb 2026 11:00:00 GMT</pubDate>
<description>SAN CARLOS, Calif., February 26, 2026--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the fourth quarter and full year 2025.</description>
</item>
<item>
<title>BeOne Medicines to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26</title>
<link>https://6ix.com/company/beigene-ltd/news/beone-medicines-announce-fourth-quarter-110000302</link>
<guid isPermaLink="true">https://6ix.com/company/beigene-ltd/news/beone-medicines-announce-fourth-quarter-110000302</guid>
<pubDate>Wed, 11 Feb 2026 11:00:00 GMT</pubDate>
<description>SAN CARLOS, Calif., February 11, 2026--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET.</description>
</item>
<item>
<title>BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/beigene-ltd/news/beone-medicines-highlights-global-oncology-110000257</link>
<guid isPermaLink="true">https://6ix.com/company/beigene-ltd/news/beone-medicines-highlights-global-oncology-110000257</guid>
<pubDate>Tue, 13 Jan 2026 11:00:00 GMT</pubDate>
<description>SAN CARLOS, Calif., January 13, 2026--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will outline the pillars of its growing global oncology leadership during its presentation today at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.</description>
</item>
<item>
<title>ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA</title>
<link>https://6ix.com/company/beigene-ltd/news/ziihera-plus-tevimbra-chemotherapy-potential-183000840</link>
<guid isPermaLink="true">https://6ix.com/company/beigene-ltd/news/ziihera-plus-tevimbra-chemotherapy-potential-183000840</guid>
<pubDate>Tue, 06 Jan 2026 18:30:00 GMT</pubDate>
<description>SAN CARLOS, Calif., January 06, 2026--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). These data, includin</description>
</item>
<item>
<title>BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/beigene-ltd/news/beone-medicines-present-44th-annual-110100546</link>
<guid isPermaLink="true">https://6ix.com/company/beigene-ltd/news/beone-medicines-present-44th-annual-110100546</guid>
<pubDate>Tue, 23 Dec 2025 11:01:00 GMT</pubDate>
<description>SAN CARLOS, Calif., December 23, 2025--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, with a presentation at 7:30 am PST.</description>
</item>
<item>
<title>BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma</title>
<link>https://6ix.com/company/beigene-ltd/news/beone-medicines-granted-u-fda-110000495</link>
<guid isPermaLink="true">https://6ix.com/company/beigene-ltd/news/beone-medicines-granted-u-fda-110000495</guid>
<pubDate>Thu, 18 Dec 2025 11:00:00 GMT</pubDate>
<description>SAN CARLOS, Calif., December 18, 2025--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment.</description>
</item>
<item>
<title>BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia</title>
<link>https://6ix.com/company/beigene-ltd/news/brukinsa-delivers-landmark-74-6-130000843</link>
<guid isPermaLink="true">https://6ix.com/company/beigene-ltd/news/brukinsa-delivers-landmark-74-6-130000843</guid>
<pubDate>Mon, 08 Dec 2025 13:00:00 GMT</pubDate>
<description>SAN CARLOS, Calif., December 08, 2025--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, reaffirms its position as the leader in chronic lymphocytic leukemia (CLL) innovation by showcasing the depth, quality, and momentum of its hematology portfolio at the 67th ASH Annual Meeting and Exposition in Orlando, Florida. The totality of BeOne’s ASH data reinforce BRUKINSA® (zanubrutinib) as the foundational Bruton’s tyrosine kinase inhibitor (BTKi) of choice.</description>
</item>
<item>
<title>Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies</title>
<link>https://6ix.com/company/beigene-ltd/news/sonrotoclax-data-ash-2025-confirm-230000354</link>
<guid isPermaLink="true">https://6ix.com/company/beigene-ltd/news/sonrotoclax-data-ash-2025-confirm-230000354</guid>
<pubDate>Sun, 07 Dec 2025 23:00:00 GMT</pubDate>
<description>SAN CARLOS, Calif., December 07, 2025--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in</description>
</item>
<item>
<title>U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma</title>
<link>https://6ix.com/company/beigene-ltd/news/u-fda-grants-priority-review-110000467</link>
<guid isPermaLink="true">https://6ix.com/company/beigene-ltd/news/u-fda-grants-priority-review-110000467</guid>
<pubDate>Wed, 26 Nov 2025 11:00:00 GMT</pubDate>
<description>SAN CARLOS, Calif., November 26, 2025--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to a New Drug Application (NDA) for sonrotoclax, a next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase (BTK) inhibitor.</description>
</item>
<item>
<title>BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025</title>
<link>https://6ix.com/company/beigene-ltd/news/beone-medicines-showcases-leadership-b-110000845</link>
<guid isPermaLink="true">https://6ix.com/company/beigene-ltd/news/beone-medicines-showcases-leadership-b-110000845</guid>
<pubDate>Thu, 20 Nov 2025 11:00:00 GMT</pubDate>
<description>SAN CARLOS, Calif., November 20, 2025--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, advances its vision to become the world’s leading oncology company with extensive new data from its differentiated hematology portfolio at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Florida, December 6-9. Nearly 50 abstracts have been accepted, including six oral presentations, featuring the company’s three transformative app</description>
</item>
<item>
<title>Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma</title>
<link>https://6ix.com/company/beigene-ltd/news/positive-phase-3-results-support-110000629</link>
<guid isPermaLink="true">https://6ix.com/company/beigene-ltd/news/positive-phase-3-results-support-110000629</guid>
<pubDate>Mon, 17 Nov 2025 11:00:00 GMT</pubDate>
<description>SAN CARLOS, Calif., November 17, 2025--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with or without PD-1 inhibitor TEVIMBRA® (tislelizumab), as first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA), including</description>
</item>
<item>
<title>BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates</title>
<link>https://6ix.com/company/beigene-ltd/news/beone-medicines-announces-third-quarter-110000262</link>
<guid isPermaLink="true">https://6ix.com/company/beigene-ltd/news/beone-medicines-announces-third-quarter-110000262</guid>
<pubDate>Thu, 06 Nov 2025 11:00:00 GMT</pubDate>
<description>SAN CARLOS, Calif., November 06, 2025--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the third quarter of 2025.</description>
</item>
<item>
<title>BeOne Medicines to Present at Upcoming Investor Conferences</title>
<link>https://6ix.com/company/beigene-ltd/news/beone-medicines-present-upcoming-investor-100100926</link>
<guid isPermaLink="true">https://6ix.com/company/beigene-ltd/news/beone-medicines-present-upcoming-investor-100100926</guid>
<pubDate>Tue, 28 Oct 2025 10:01:00 GMT</pubDate>
<description>SAN CARLOS, Calif., October 28, 2025--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in fireside chats at two upcoming investor conferences:</description>
</item>
<item>
<title>BeOne Medicines to Announce Third Quarter 2025 Financial Results on November 6</title>
<link>https://6ix.com/company/beigene-ltd/news/beone-medicines-announce-third-quarter-100100962</link>
<guid isPermaLink="true">https://6ix.com/company/beigene-ltd/news/beone-medicines-announce-third-quarter-100100962</guid>
<pubDate>Wed, 22 Oct 2025 10:01:00 GMT</pubDate>
<description>SAN CARLOS, Calif., October 22, 2025--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its third quarter 2025 financial results on Thursday, November 6, 2025 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET.</description>
</item>
<item>
<title>BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 2025</title>
<link>https://6ix.com/company/beigene-ltd/news/beone-medicines-presents-data-tevimbra-100000588</link>
<guid isPermaLink="true">https://6ix.com/company/beigene-ltd/news/beone-medicines-presents-data-tevimbra-100000588</guid>
<pubDate>Mon, 20 Oct 2025 10:00:00 GMT</pubDate>
<description>SAN CARLOS, Calif., October 20, 2025--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of data from two pivotal Phase 3 trials – RATIONALE-307 and 312 – offering new evidence of the benefits of its PD-1 inhibitor, TEVIMBRA® (tislelizumab), at the European Society of Medical Oncology 2025 Congress (ESMO 2025) in Berlin, Germany, October 17-21. The results reinforce TEVIMBRA’s consistent and durable efficacy across lung cance</description>
</item>
<item>
<title>BeOne Medicines’ Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA</title>
<link>https://6ix.com/company/beigene-ltd/news/beone-medicines-sonrotoclax-granted-breakthrough-100000323</link>
<guid isPermaLink="true">https://6ix.com/company/beigene-ltd/news/beone-medicines-sonrotoclax-granted-breakthrough-100000323</guid>
<pubDate>Mon, 13 Oct 2025 10:00:00 GMT</pubDate>
<description>SAN CARLOS, Calif., October 13, 2025--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL). Additionally, the FDA has accepted BeOne’s request for partici</description>
</item>
<item>
<title>BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)</title>
<link>https://6ix.com/company/beigene-ltd/news/beone-medicines-announces-positive-topline-100000843</link>
<guid isPermaLink="true">https://6ix.com/company/beigene-ltd/news/beone-medicines-announces-positive-topline-100000843</guid>
<pubDate>Fri, 29 Aug 2025 10:00:00 GMT</pubDate>
<description>SAN CARLOS, Calif., August 29, 2025--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans to present the fu</description>
</item>
<item>
<title>European Commission Approves TEVIMBRA® as Neoadjuvant/Adjuvant NSCLC Treatment Ahead of Late-Breaking Data Presentation at WCLC 2025</title>
<link>https://6ix.com/company/beigene-ltd/news/european-commission-approves-tevimbra-neoadjuvant-100000321</link>
<guid isPermaLink="true">https://6ix.com/company/beigene-ltd/news/european-commission-approves-tevimbra-neoadjuvant-100000321</guid>
<pubDate>Wed, 27 Aug 2025 10:00:00 GMT</pubDate>
<description>SAN CARLOS, Calif., August 27, 2025--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission (EC) has approved TEVIMBRA (tislelizumab), in combination with platinum-containing chemotherapy as neoadjuvant treatment followed by TEVIMBRA monotherapy as adjuvant treatment, for adult patients with resectable non-small cell lung cancer (NSCLC) at high risk of recurrence. The EC approval is based on results from the Phase 3 R</description>
</item>
<item>
<title>BeOne to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference</title>
<link>https://6ix.com/company/beigene-ltd/news/beone-present-morgan-stanley-23rd-100100891</link>
<guid isPermaLink="true">https://6ix.com/company/beigene-ltd/news/beone-present-morgan-stanley-23rd-100100891</guid>
<pubDate>Tue, 26 Aug 2025 10:01:00 GMT</pubDate>
<description>SAN CARLOS, Calif., August 26, 2025--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025, with a fireside chat at 1:50 p.m. EDT.</description>
</item>
</channel>
</rss>